You need to load/activate the cURL extension (http://www.php.net/cURL).
Drug nameNilutamide
DescriptionNilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
DrugBankPrimary Accession Number: DB00665
DIN02221861
TypeApproved, Small Molecule
IndicationFor use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2)
Mechanism of ActionNilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
AbsorptionRapidly and completely absorbed, yielding high and persistent plasma concentrations.
ToxicitySymptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
Protein BindingNot available